Shanghai Pharmaceuticals' Subsidiary Receives Clinical Trial Approval for Treprostinil Diethanolamine Inhalation Powder

Stock News11-04

Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shangyao Ruier Pharmaceutical Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for Treprostinil Diethanolamine Inhalation Powder.

Treprostinil Diethanolamine Inhalation Powder is a Class 2.2 improved innovative drug, with the active ingredient being treprostinil diethanolamine, a synthetic prostacyclin derivative. It is intended for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to alleviate exercise-induced symptoms. Its mechanism of action primarily involves directly dilating pulmonary and systemic arterial vascular beds and inhibiting platelet aggregation.

As of the date of this announcement, the project has accumulated research and development expenses of approximately 21.41 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment